Major (≈84%) CYP1A2 metabolite of caffeine — N3-demethylated to 1,7-dimethylxanthine. A non-selective adenosine receptor antagonist (Ki at A1/A2A within 2-3× of caffeine itself) and a phosphodiesterase inhibitor. Responsible for a substantial fraction of caffeine's late-half-life CNS effects since paraxanthine accumulates in plasma while caffeine drops. Trialed as a stand-alone supplement / nootropic with claims of cleaner subjective tolerability than caffeine — less anxiogenic effect at equivalent A2A occupancy. PK (Lelo 1986 PMID:3741224 + caffeine metabolism literature): Caffeine's major 1-N-demethylated metabolite (CYP1A2 product — cross-link: caffeine_demethylation pathway); also dosed directly as a research/supplement compound. t½ 3-4 h, Tmax 1-2 h, F estimated 70% from PO-dosed studies. Apparent Vd 40 L. CYP1A2 substrate same as caffeine parent (smokers/inducers clear faster); minimal CYP-perpetrator activity. Pharmacology similar to caffeine but more A2A-selective + claims of reduced anxiety vs caffeine (limited human data).
Half-Life & Elimination Curve (PO: 3.1h)
Plasma (PO)t½ Decay (3.1h)
0×t½0h100%(1.19 mg/L)
1×t½3.1h50%(0.596 mg/L)
2×t½6.2h25%(0.298 mg/L)
3×t½9.3h12.5%(0.149 mg/L)
4×t½12.4h6.3%(74.4 µg/L)
5×t½15.5h3.1%(37.2 µg/L)
Elimination t½3.1h (PO)
Rate Constant (ke)0.224 h⁻¹
Time to Peak (Tmax)1.72h
Est. Peak (Cmax)1.19 mg/L
Clearance (CL)8.94 L/h
97% Washout (5×t½)15.5h
Dosing Guidelines
Oral (PO): Typical 100 mg (Range: 50–300 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 70% · Volume of Distribution (Vd): 40 L · Absorption (ka): 1.2 h⁻¹ (t½ka ≈ 35m) [PMID 3756065]